Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer

Zahra Gohari, Lora Stojanovic, Feyruz V. Rassool

Cancer Res (2025) 85 (10): 1747–1749.

https://doi.org/10.1158/0008-5472.CAN-25-0831

Published: 15 May 2025

View articletitled, Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer

Journal Articles

Abstract CT191: Intravenous infusion of the allosteric small molecule STING agonist CRD3874-SI in patients with relapsed or refractory acute myeloid leukemia: A phase I trial

Cancer Res (2025) 85 (8_Supplement_2): CT191.

https://doi.org/10.1158/1538-7445.AM2025-CT191

Published: 25 April 2025

View articletitled, Abstract CT191: Intravenous infusion of the allosteric small molecule STING agonist CRD3874-SI in patients with relapsed or refractory acute myeloid leukemia: A phase I trial

Journal Articles

Abstract 4844: Epigenetic reprogramming of the STING pathway as a combination strategy in high grade serous ovarian cancer

Saranya Rajendran, Elnaz Abbasi Farid, Kaushlendra Tripathi, Ishani Chattopadhayay, Shu Zhang, Stephen B. Baylin, Feyruz V. Rassool, Kenneth P. Nephew

Cancer Res (2025) 85 (8_Supplement_1): 4844.

https://doi.org/10.1158/1538-7445.AM2025-4844

Published: 21 April 2025

View articletitled, Abstract 4844: Epigenetic reprogramming of the STING pathway as a combination strategy in high grade serous ovarian cancer

Journal Articles

Abstract 1698: Synergy with decitabine expands the utility of talazoparib: A novel therapeutic strategy for BRCA-proficient pancreatic cancer

Zachery Keepers, Brandon Carter-Cooper, Hurley Ryan, Stephen B. Baylin, Rena Lapidus, Feyruz V. Rassool, Hem D. Shukla, Aaron T. Ciner

Cancer Res (2025) 85 (8_Supplement_1): 1698.

https://doi.org/10.1158/1538-7445.AM2025-1698

Published: 21 April 2025

View articletitled, Abstract 1698: Synergy with decitabine expands the utility of talazoparib: A novel therapeutic strategy for BRCA-proficient pancreatic cancer

Journal Articles

ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer

Cancer Res (2025) 85 (7): 1183–1198.

https://doi.org/10.1158/0008-5472.CAN-24-1286

Published: 03 April 2025

View articletitled, ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer

Includes: Supplementary data

Journal Articles

Abstract PR001: ZNFX1 is a master regulator and tumor suppressor in epigenetically-induced pathogen mimicry, mitochondrial dysfunction and STING-dependent signaling in cancer

Feyruz V Rassool, Lora Stojanovic, Rachel Abbotts, Kaushlendra Tripathi, Saranya Rajendran, Colin M Coon, Elnaz Abbasi, Sheng Liu, Jun Wan, Michael J Topper, Stephen B Baylin, Kenneth P Nephew

Cancer Res (2025) 85 (3_Supplement): PR001.

https://doi.org/10.1158/1538-7445.DNAMETHYLATION-PR001

Published: 01 February 2025

View articletitled, Abstract PR001: ZNFX1 is a master regulator and tumor suppressor in epigenetically-induced pathogen mimicry, mitochondrial dysfunction and STING-dependent signaling in cancer

Journal Articles

Abstract PR-005: ZNFX1 is a master regulator for epigenetic reprograming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells

Lora Stojanovic, Rachel Abbotts, Kaushlendra Tripathi, Collin M. Coon, Sheng Liu, Jun Wan, Michael J. Topper, Kenneth P. Nephew, Stephen B. Baylin, Feyruz V. Rassool

Cancer Res (2024) 84 (5_Supplement_2): PR-005.

https://doi.org/10.1158/1538-7445.OVARIAN23-PR-005

Published: 04 March 2024

View articletitled, Abstract PR-005: ZNFX1 is a master regulator for epigenetic reprograming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells

Journal Articles

Abstract 2678: LLL12B, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer cells

Li Pan, Xiang Chen, Feyruz V. Rassool, Chenglong Li, Jiayuh Lin

Cancer Res (2022) 82 (12_Supplement): 2678.

https://doi.org/10.1158/1538-7445.AM2022-2678

Published: 15 June 2022

View articletitled, Abstract 2678: LLL12B, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer cells

Journal Articles

Abstract 5593: DNMT inhibitor induces NSCLC inflammasome signaling and mitochondrial dysfunction, producing to DSB repair defects and PARP inhibitor sensitivity

Rachel Abbotts, Lora Stojanovic, Michael J. Topper, Brian M. Polster, Stephen B. Baylin, Feyruz V. Rassool

Cancer Res (2022) 82 (12_Supplement): 5593.

https://doi.org/10.1158/1538-7445.AM2022-5593

Published: 15 June 2022

View articletitled, Abstract 5593: DNMT inhibitor induces NSCLC inflammasome signaling and mitochondrial dysfunction, producing to DSB repair defects and PARP inhibitor sensitivity

Journal Articles

Abstract 6301: DNA methyltransferase inhibitors increase ERV reactivation and STING-dependent interferon/inflammasome signaling in TP53 mutant AML

Aksinija A. Kogan, Michael J. Topper, Lora Stojanovic, Lena J. McLaughlin, Tammy J. Kingsbury, Maria R. Baer, Michael Kessler, Stephen B. Baylin, Feyruz V. Rassool

Cancer Res (2022) 82 (12_Supplement): 6301.

https://doi.org/10.1158/1538-7445.AM2022-6301

Published: 15 June 2022

View articletitled, Abstract 6301: DNA methyltransferase inhibitors increase ERV reactivation and STING-dependent interferon/inflammasome signaling in TP53 mutant AML

Journal Articles

Abstract 1428: PARP inhibitor resensitizes TKI-resistant AML to TKI

Anna J. Dellomo, Rena G. Lapidus, Mariusz Karbowski, Maria R. Baer, Tami J. Kingsbury, Feyruz V. Rassool

Cancer Res (2021) 81 (13_Supplement): 1428.

https://doi.org/10.1158/1538-7445.AM2021-1428

Published: 01 July 2021

View articletitled, Abstract 1428: PARP inhibitor resensitizes TKI-resistant AML to TKI

Journal Articles

How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML

Heather M. O'Hagan, Feyruz V. Rassool, Kenneth P. Nephew

Cancer Res (2021) 81 (4): 813–815.

https://doi.org/10.1158/0008-5472.CAN-20-4108

Published: 15 February 2021

View articletitled, How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML

Journal Articles

Abstract 969: Pharmacologic induction of innate immune signaling via STING directly drives homologous recombination deficiency

Lena J. McLaughlin, Aksinija A. Kogan, Stephen B. Baylin, Michael J. Topper, Feyruz V. Rassool

Cancer Res (2020) 80 (16_Supplement): 969.

https://doi.org/10.1158/1538-7445.AM2020-969

Published: 15 August 2020

View articletitled, Abstract 969: Pharmacologic induction of innate immune signaling via STING directly drives homologous recombination deficiency

Journal Articles

Abstract 4473: DNMT and PARP inhibitor combination therapy induces an interferon-driven homologous recombination defect in triple-negative breast cancers and acute myeloid leukemia

Lena J. McLaughlin, Aksinija A. Kogan, Eun Yong Choi, Rena S. Lapidus, Ying Zou, Huili Li, Stephen B. Baylin, Michael J. Topper, Feyruz V. Rassool

Cancer Res (2019) 79 (13_Supplement): 4473.

https://doi.org/10.1158/1538-7445.AM2019-4473

Published: 01 July 2019

View articletitled, Abstract 4473: DNMT and PARP inhibitor combination therapy induces an interferon-driven homologous recombination defect in triple-negative breast cancers and acute myeloid leukemia

Journal Articles

Abstract IA13: Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for multiple cancers: Key data in AML and triple negative breast cancer

Nidal Muvarak, Khadiza Chowdhury, Carine Robert, Xia Limin, Eun Yong Choi, Yi Cai, Marina Bellani, Michael Seidman, Maria R. Baer, Rena Lapidus, Stephen B. Baylin, Feyruz V. Rassool

Cancer Res (2017) 77 (22_Supplement): IA13.

https://doi.org/10.1158/1538-7445.NEWFRONT17-IA13

Published: 14 November 2017

View articletitled, Abstract IA13: Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for multiple cancers: Key data in AML and triple negative breast cancer

Journal Articles

Abstract 1422: Enhancing the therapeutic effects of PARP inhibitors in combination DNA methyl transferase inhibitors, using low doses of ionizing radiation in non small cell lung cancers

Christopher Biondi, Daniel Fontaine, Lora Stojanovic, Pratik Nagaria, Rena Lapidus, Eun Yong Choi, Javed Mahmood, Stephen Baylin, Feyruz V. Rassool

Cancer Res (2017) 77 (13_Supplement): 1422.

https://doi.org/10.1158/1538-7445.AM2017-1422

Published: 01 July 2017

View articletitled, Abstract 1422: Enhancing the therapeutic effects of PARP inhibitors in combination DNA methyl transferase inhibitors, using low doses of ionizing radiation in non small cell lung cancers

Journal Articles

Abstract 2478: PARP trapping by PARP inhibitors have distinct effects on HR and ALT NHEJ DSB repair, potentially impacting its therapeutic efficacy in breast cancers

Bryan M. Pelkey, Pratik Nagaria, Feyruz V. Rassool

Cancer Res (2017) 77 (13_Supplement): 2478.

https://doi.org/10.1158/1538-7445.AM2017-2478

Published: 01 July 2017

View articletitled, Abstract 2478: PARP trapping by PARP inhibitors have distinct effects on HR and ALT NHEJ DSB repair, potentially impacting its therapeutic efficacy in breast cancers

Journal Articles

Abstract 4145: Concurrent treatment with Pim kinase inhibitor decreases alternative non-homologous end-joining repair of DNA damage induced by topoisomerase 2 inhibitors in cells with FLT3-ITD

Kshama A. Doshi, Pratik K. Nagaria, Adriana E. Tron, Feyruz V. Rassool, Maria R. Baer

Cancer Res (2017) 77 (13_Supplement): 4145.

https://doi.org/10.1158/1538-7445.AM2017-4145

Published: 01 July 2017

View articletitled, Abstract 4145: Concurrent treatment with Pim kinase inhibitor decreases alternative non-homologous end-joining repair of DNA damage induced by topoisomerase 2 inhibitors in cells with FLT3-ITD

Journal Articles

Abstract 4045: Decreased Fanconi anemia gene expression contributes to efficacy of PARP and DNMT inhibitor combination therapy in triple negative breast cancer

Lena J. McLaughlin, Huili Li, Pratik Nagaria, Stephen B. Baylin, Cynthia A. Zahnow, Feyruz V. Rassool

Cancer Res (2017) 77 (13_Supplement): 4045.

https://doi.org/10.1158/1538-7445.AM2017-4045

Published: 01 July 2017

View articletitled, Abstract 4045: Decreased Fanconi anemia gene expression contributes to efficacy of PARP and DNMT inhibitor combination therapy in triple negative breast cancer

Journal Articles

Abstract LB-205: Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for poor prognosis acute myeloid leukemia and triple-negative breast cancers

Feyruz V. Rassool, Nidal Muvarak, Khadiza Chowdury, Carine Robert, Limin Xia, Eun Yong Choi, Yi Cai, Marina Bellani, Ying Zou, Michael Seidman, Søren Bentzen, Maria Baer, Rena Lapidus, Stephen B. Baylin

Cancer Res (2016) 76 (14_Supplement): LB-205.

https://doi.org/10.1158/1538-7445.AM2016-LB-205

Published: 15 July 2016

View articletitled, Abstract LB-205: Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for poor prognosis acute myeloid leukemia and triple-negative breast cancers

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Combining STING Agonists with PARP Inhibitors Mounts an NK-Dependent Defense against Therapy-Resistant Breast Cancer

Abstract CT191: Intravenous infusion of the allosteric small molecule STING agonist CRD3874-SI in patients with relapsed or refractory acute myeloid leukemia: A phase I trial

Abstract 4844: Epigenetic reprogramming of the STING pathway as a combination strategy in high grade serous ovarian cancer

Abstract 1698: Synergy with decitabine expands the utility of talazoparib: A novel therapeutic strategy for BRCA-proficient pancreatic cancer

ZNFX1 Functions as a Master Regulator of Epigenetically Induced Pathogen Mimicry and Inflammasome Signaling in Cancer

Abstract PR001: ZNFX1 is a master regulator and tumor suppressor in epigenetically-induced pathogen mimicry, mitochondrial dysfunction and STING-dependent signaling in cancer

Abstract PR-005: ZNFX1 is a master regulator for epigenetic reprograming of mitochondrial inflammasome signaling and pathogen mimicry in cancer cells

Abstract 2678: LLL12B, a novel small molecule STAT3 inhibitor induces apoptosis and suppresses cell migration and tumor growth in triple-negative breast cancer cells

Abstract 5593: DNMT inhibitor induces NSCLC inflammasome signaling and mitochondrial dysfunction, producing to DSB repair defects and PARP inhibitor sensitivity

Abstract 6301: DNA methyltransferase inhibitors increase ERV reactivation and STING-dependent interferon/inflammasome signaling in TP53 mutant AML

Abstract 1428: PARP inhibitor resensitizes TKI-resistant AML to TKI

How Epigenetic Therapy Beats Adverse Genetics in Monosomy Karyotype AML

Abstract 969: Pharmacologic induction of innate immune signaling via STING directly drives homologous recombination deficiency

Abstract 4473: DNMT and PARP inhibitor combination therapy induces an interferon-driven homologous recombination defect in triple-negative breast cancers and acute myeloid leukemia

Abstract IA13: Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for multiple cancers: Key data in AML and triple negative breast cancer

Abstract 1422: Enhancing the therapeutic effects of PARP inhibitors in combination DNA methyl transferase inhibitors, using low doses of ionizing radiation in non small cell lung cancers

Abstract 2478: PARP trapping by PARP inhibitors have distinct effects on HR and ALT NHEJ DSB repair, potentially impacting its therapeutic efficacy in breast cancers

Abstract 4145: Concurrent treatment with Pim kinase inhibitor decreases alternative non-homologous end-joining repair of DNA damage induced by topoisomerase 2 inhibitors in cells with FLT3-ITD

Abstract 4045: Decreased Fanconi anemia gene expression contributes to efficacy of PARP and DNMT inhibitor combination therapy in triple negative breast cancer

Abstract LB-205: Combination of DNA methyltransferase and PARP inhibitors as a novel therapy strategy for poor prognosis acute myeloid leukemia and triple-negative breast cancers

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only